Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.70M |
| Operating Margin | 0.00% |
| Return on Equity | -326.90% |
| Return on Assets | -99.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.53 |
| Price-to-Book | 1.88 |
| Price-to-Sales (TTM) | 9.78 |
| EV/Revenue | 1.872 |
| EV/EBITDA | -0.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.82M |
| Float | $14.04M |
| % Insiders | 0.11% |
| % Institutions | 5.33% |
Volatility is currently expanding